ResMed acquires home sleep testing company Ectosense
Ectosense’s NightOwl is a leading cloud-connected home sleep apnea test
Ectosense’s NightOwl is a leading cloud-connected home sleep apnea test
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
Anti-malaria API facility will be operational in 15-18 months
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The Subsidiary has received one inspectional observation in Form 483
Subscribe To Our Newsletter & Stay Updated